Evidence across cardiovascular, renal, oncological and neurological disorders shows that excess XO-derived ROS, rather than UA itself, is a likely mediator of tissue injury and clinical progression, with several lines of research linking them to the interplay between XOR and purinergic signaling. This evidence concerns the gene XDH and nervous system disorder.